MONTREAL AND SHERBROOKE, QC, March 28, 2014 /CNW Telbec/ - Cyclenium Pharma Inc., a newly formed pharmaceutical company
specializing in the research and development of novel drug candidates
based on proprietary macrocyclic chemistry, today announced the opening
of its laboratories at the NEOMED Institute in Montreal, Canada.
Founded by management and scientists from the pioneering macrocyclic
drug discovery and development company, Tranzyme Pharma, which recently
closed its Sherbrooke R & D site, Cyclenium is capitalizing on fifteen
years of experience and expertise in macrocycle chemistry and targeting
creation of a second generation technology that addresses the
limitations of the initial efforts in this field.
"We are very pleased with this opportunity to jump start our R & D
efforts at the NEOMED Institute," said Dr. Helmut Thomas, President and
CEO of Cyclenium Pharma. "The location is ideal in providing a host of
services that would otherwise be beyond the reach of a start-up
enterprise. This will permit us to concentrate our attention on rapidly
building our capabilities and developing our breakthrough next
generation macrocyclic library."
The NEOMED Institute is a dedicated center of excellence for drug R&D.
It offers a high quality environment with access to highly specialized
equipment. It also encourages synergies between resident companies
leading to collaborative projects. Since its inception in November
2012, the Institute is now host to 17 life sciences companies.
"We are delighted to welcome Cyclenium Pharma into the NEOMED Institute
and are confident that its research work in macrocycle chemistry will
be successful," said Max Fehlmann, President and CEO of the NEOMED
Institute. "Cyclenium is the type of innovative company we seek to
nurture and is a strong addition to our roster of resident companies."
About Cyclenium Pharma
Cyclenium Pharma is an emerging pharmaceutical research and development
company pursuing development of selected product opportunities in areas
of unsatisfied medical need, while simultaneously creating a second
generation macrocyclic drug discovery technology. Cyclenium is building
value through progression of our internal programs and establishing
collaborations with innovative pharmaceutical and biotechnology
companies seeking to modulate difficult disease targets. For more on
Cyclenium Pharma, please see: www.cyclenium.com.
About the NEOMED Institute
The NEOMED Institute is a state-of-the-art R&D facility in the Montreal
Technoparc. The Institute acts as an open-access drug discovery hub
hosting drug discovery and development research companies, providing a
unique environment to foster innovation, collaboration and creativity.
For more information, please visit: www.neomed.ca
SOURCE: Cyclenium Pharma Inc.
For further information:
Helmut Thomas, Ph.D.
President & CEO
Cyclenium Pharma Inc.
Telephone: + 1 514-745-1439
Mounia Azzi, Ph.D.
Director of Scientific Affairs
The NEOMED Institute (Canada)
Telephone: +1 514-267-1212, ext. 202